Severe Health Risks Follow Adults Who Were Diagnosed With Nonalcoholic Fatty Liver Disease As Children
Posted on: Tuesday, 28 October 2008, 09:00 CDT
SAN FRANCISCO, Oct. 28 /PRNewswire/ -- The goal of researchers from the Mayo Clinic in Rochester, MN, led by Dr. Paul Angulo, was to determine the effects of fatty liver disease in children up to 20 years after the initial diagnosis. This is especially important as nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver disease in preadolescents and adolescents. To put the problem of NAFLD into perspective, Ariel Feldstein, MD, another investigator involved with the study said, "In the past ten years, the rate of obesity in our country has tripled in children and teenagers, and this most likely explains why NAFLD is becoming so common. Some experts estimate that about half of obese children may have fatty liver disease."
The authors identified 66 children who were diagnosed with NAFLD and had extensive follow up data available for review. After the initial diagnosis, four children developed type 2 diabetes and four children had increased liver fibrosis. During follow up two children developed end-stage liver disease and required a liver transplantation. However NAFLD recurred in the transplanted liver in the two cases, with one case progressing to cirrhosis and requiring re-transplantation. The study demonstrated that NAFLD in children is associated with a significantly shorter long-term survival as compared to the expected survival of the general population. Children with NAFLD had an almost 14-fold higher risk of dying or requiring liver transplantation than the general population of same age and sex.
"There is currently no medication proven to be effective for NAFLD," development of medications that could treat NAFLD and NASH is an area of intense research," said Dr. Feldstein, "and it remains unclear whether there are any clinical or laboratory features that can be used to identify the subgroup of children with NAFLD that will develop advanced liver disease later in life."
"The most important recommendations for children with fatty liver are to lose weight if they are overweight or obese, increase their physical activity, follow a balanced diet and avoid unnecessary medications," concluded Dr. Feldstein.
Abstract title:
The natural history of nonalcoholic fatty liver disease in children: A follow-up study up to 20 years.
AASLD is the leading medical organization for advancing the science and practice of hepatology. Founded by physicians in 1950, AASLD's vision is to prevent and cure liver diseases. This year's Liver Meeting, held in San Francisco, California, October 31 - November 4, will bring together more than 7,000 researchers from 55 countries.
A pressroom will be available from November 1 at the annual meeting. For copies of abstracts and press releases, or to arrange for pre-conference research interviews contact Gregory Bologna at 703-299-9766. To pre-register, call Ann Tracy at 703-299-9766.
Press releases and all abstracts are available online at http://www.aasld.org/ .
This release was issued through The Xpress Press News Service, merging e-mail and satellite distribution technologies to reach business analysts and media outlets worldwide. For more information, visit http://www.xpresspress.com/
American Association for the Study of Liver Diseases
CONTACT: Media: Gregory Bologna, +1-703-299-9766, gbologna@aasld.org,Press Room: November 1-4, 2008, Room: 2020, +1-415-348-4403; Researcher ArielFeldstein, MD, +1-216-444-5348, feldsta@ccf.org
Web site: http://www.aasld.org/
Source: PRNewswire
Related Articles
- UPDATE: US Oncology Research Network Participates in Phase III Follow-up Study to BiPar's Investigational Cancer Drug BSI-201
- Connection Between Migraines And Reduced Breast Cancer Risk Confirmed In Follow-Up Study
- Parkinson's Disease Market Upgrade Following Evidence of Disease Slowing With Azilect
- American Association for the Study of Liver Diseases (AASLD) President's Press Conference, Nov. 1, 2008 in San Francisco
- Enrollment Complete in 15-Year Long-Term Follow-Up Study Evaluating Impact of AVONEX(R) in Patients With Relapsing Multiple Sclerosis
- Nymox Concludes Two Year Follow-Up Study of Hyperplasia Drug
- Nymox Reports Completion of Large New 2 Year Follow-Up Study of NX-1207 for BPH
- Nymox Reports Completion of New 42 Month Follow-Up Study of NX-1207 for BPH
- Reports Faults Drug Follow-Up Studies
- Randomized, Controlled Trial of Dexamethasone in Neonatal Chronic Lung Disease: 13- to 17-Year Follow-Up Study: I. Neurologic, Psychological, and Educational Outcomes
User Comments (0)

RSS Feeds